theMarketing Calendar
Log inSign up
← All days
day · fixed · day 138 of 365

Global Porphyria Day

Porphyria might sound unfamiliar, but for those living with it, the effects are very real. It is not one single diagnosis.

Body & HealthHealthcareLife & Living35
Marketing angleinferred

Position your brand as a rare-disease advocate by amplifying porphyria awareness through purple-themed campaigns and educational content that drives recognition and symptom literacy.

Relevance 35low intent
  • Purple Awareness Challenge: encourage employees and customers to wear purple on May 18 and share their 'why' stories on social media
  • Educational Spotlight: partner with healthcare providers to create symptom-recognition guides and medication-safety resources for porphyria communities
  • Lighting for Visibility: coordinate purple building/storefront lighting on Global Porphyria Day to signal community support and spark local conversations

History

Global Porphyria Day was launched in the early 2020s by the United Porphyrias Association and several international partners. These groups wanted to give porphyria a stronger global voice and create a shared moment when patients, caregivers, clinicians, and advocates could speak in unison.

They chose May 18 as a dedicated date to bring people together. Before that, many awareness efforts were spread across longer campaigns and rare disease observances.

Those broader efforts were valuable, but porphyria communities wanted a clearer focal point, one that helped people remember the name and recognize the symptoms. A single day also makes it easier for organizations to coordinate messaging, for individuals to plan their own participation, and for the wider public to notice a concentrated wave of purple.

The name “porphyria” comes from a Greek word associated with purple, a nod to the purplish pigments involved in the condition. That connection is one reason purple became the symbol of the movement. Purple ribbons, lights, clothing, and graphics now function like a shorthand: they create instant recognition for an illness that otherwise stays hidden behind complex medical terms.

Global Porphyria Day was also developed around a clear patient reality: diagnosis can be slow. Porphyria symptoms can mimic common conditions, and different types of porphyria show up in different body systems. Some people experience severe abdominal pain, vomiting, constipation, rapid heart rate, or confusion during acute attacks.

Others deal with fragile skin, blistering, scarring, and changes in skin pigmentation after sun exposure. Because these patterns can overlap with other disorders, people may be treated for the wrong problem for a long time, which can be exhausting and sometimes dangerous.

In many cases, triggers play a major role. Certain medications, alcohol, hormonal shifts, infections, fasting or crash dieting, and stress can set off attacks in susceptible individuals, especially in acute hepatic porphyrias.

That is why awareness is not only about recognition. It is about safety. When health professionals and patients know porphyria is a possibility, they can make better decisions about testing, referrals, and avoiding known triggers.

As the day gained momentum, the emphasis naturally expanded beyond the disease label itself. The messaging focused on the lived experience: emergency visits that end with no clear answers, the fear of symptoms returning, the challenge of explaining dietary limitations or sun avoidance to friends, and the emotional weight of being doubted.

Campaign language such as “real people, real pain” captured a truth patients often need others to grasp. Rare does not mean mild. Invisible does not mean imagined.

Global participation became part of the day’s identity. Porphyria is rare everywhere, which can leave individuals feeling isolated in their own communities. A shared awareness day helps connect the dots across countries and languages. It gives patients a chance to find others who understand, caregivers a chance to compare notes, and clinicians a chance to see the broader picture of how these conditions affect daily life.

Educational tools are often central to the day. Many communities use the opportunity to explain that porphyria is a group of disorders with different subtypes, and that diagnosis typically relies on specific lab testing during symptomatic periods.

That detail matters because timing can affect results, and it can prevent people from being told incorrectly that “nothing is wrong.” The day also encourages a practical form of preparedness: keeping a clear medical summary, knowing which symptoms signal an emergency, and discussing medication safety with healthcare providers.

Over time, the color purple became more than a symbol. It became a way to make space for a community that has spent too long in the margins. Global Porphyria Day continues to center on connection, better understanding, and the steady push toward earlier diagnosis and better care.

It reminds people affected by porphyria that they are not alone and reminds everyone else that learning about rare diseases is one of the simplest ways to show up for a neighbor they may never have realized needed support.


How to celebrate

Wear Purple with Purpose

Color can spark conversations that facts alone cannot. Dressing in purple shows quiet support for those who rarely feel seen. When someone asks why, use that moment to explain porphyria in plain language. It can help to mention that some types primarily affect the liver and can trigger painful “attacks,” while other types primarily affect the skin and can cause blistering and extreme light sensitivity. Some people experience both. Keeping the explanation simple does not diminish the seriousness. It makes the topic accessible. To make it even more purposeful, pair the purple with a short message on a pin, a sticker, or a note in a workplace chat. Something like “Ask me about porphyria” opens the door for curiosity without pressure. If the conversation goes deeper, it can also be helpful to share one key point: porphyria is rare, but prompt recognition matters because certain medications and other triggers can make symptoms worse.

Let Your Space Speak

Lighting a porch, window, or building in purple turns your space into a message. Even a single bulb sends a signal. It tells people living with porphyria that their stories matter. It also invites others to ask and learn more, which is exactly what awareness needs. Purple lighting can be as simple as a small lamp or as ambitious as coordinated lights at a community venue. The goal is visibility, not perfection. A “quiet” version works too. A purple tablecloth at a gathering, a purple ribbon on a bulletin board, or a purple-themed display at work can prompt questions in a low-key way. For people living with light sensitivity, it also helps to be mindful of bright flashing lights and instead choose gentle, steady illumination.

Lift Up Real Voices

Social media moves fast, but true stories stick. Sharing a personal post or reposting someone else’s helps break the silence. Use words that explain what most people never see: the fear of symptoms that arrive without warning, the delay in diagnosis, the frustration of normal-looking lab results, the mental load of avoiding triggers, and the strength it takes to keep going. These stories are not “oversharing.” They are a form of education. For supporters who do not have porphyria, it is still possible to amplify voices respectfully. Focus on listening first, then sharing messages created by people who live with the condition. When posting, consider adding practical takeaways: porphyria can be genetic, attacks can be medical emergencies, and sunlight sensitivity is not “just a sunburn.” Those details turn sympathy into understanding.

Turn Action into Care

A fundraiser does not have to be big to make a difference. A bake sale, a donation jar, a craft sale, or even a shared message encouraging support for patient organizations helps move research and services forward. Each dollar supports work that can ease pain, speed up answers, or make future treatments possible. It can also support practical needs like patient education, peer support programs, and resources that help people navigate work, school, and medical systems. Action can also look like advocacy. Encourage a local clinic, pharmacy, or student group to host a short educational session about rare diseases and medication safety. Porphyria is a clear example of why rare conditions deserve attention: the right choice in a crisis, including the right medication, can prevent complications.

Bring People Together

Organizing a small gathering can make a huge impact. Over food, music, or a craft table, people can learn in a way that feels human rather than clinical. Whether it is friends in a living room or coworkers in a lunchroom, shared moments open hearts faster than facts alone. A simple theme like “Purple Potluck” keeps things light, while the conversation stays meaningful. For a more supportive gathering, consider building in comfort. Some people with porphyria manage fatigue, pain, nausea, or sensitivity to light. Choose a calm environment, keep scents minimal, and offer seating and shade. A thoughtful host can turn “awareness” into actual inclusion. If the group wants an activity, a storytelling circle works well. Participants can share a moment when they learned something new about invisible illness, caregiving, or navigating the health system. The point is not to compare suffering. It is to practice empathy and to normalize believing people when they describe symptoms that others cannot see. Global Porphyria Day Timeline1871Early clinical and biochemical description of porphyriaGerman physician Felix Hoppe-Seyler reports patients with dark-red urine and neurologic symptoms and links these findings to excess “hematoporphyrin,” helping define acute porphyria as a distinct clinical entity. [1]1937Key steps of heme synthesis are elucidatedBuilding on earlier work, David Shemin and colleagues trace how simple precursors are incorporated into heme, clarifying the biosynthetic pathway whose enzyme defects later explain various porphyrias. [1]1961Acute intermittent porphyria enzyme defect identifiedResearchers show that acute intermittent porphyria is associated with reduced activity of porphobilinogen deaminase, establishing one of the first direct links between a specific enzyme deficiency and a human porphyria. [1]1980sMolecular genetics enables DNA diagnosis of porphyriasCloning of heme pathway genes and discovery of disease-causing mutations begin to allow DNA-based diagnosis and family screening for several porphyrias, improving risk stratification and genetic counseling. [1]2019First RNA interference therapy for acute hepatic porphyriaThe U.S. Food and Drug Administration approves givosiran, an RNA interference drug that targets hepatic ALAS1, providing a novel treatment option that reduces the frequency of attacks in adults with acute hepatic porphyria.

Early clinical and biochemical description of porphyria

German physician Felix Hoppe-Seyler reports patients with dark-red urine and neurologic symptoms and links these findings to excess “hematoporphyrin,” helping define acute porphyria as a distinct clinical entity. [1]

Key steps of heme synthesis are elucidated

Building on earlier work, David Shemin and colleagues trace how simple precursors are incorporated into heme, clarifying the biosynthetic pathway whose enzyme defects later explain various porphyrias. [1]

Acute intermittent porphyria enzyme defect identified

Researchers show that acute intermittent porphyria is associated with reduced activity of porphobilinogen deaminase, establishing one of the first direct links between a specific enzyme deficiency and a human porphyria. [1]

Molecular genetics enables DNA diagnosis of porphyrias

Cloning of heme pathway genes and discovery of disease-causing mutations begin to allow DNA-based diagnosis and family screening for several porphyrias, improving risk stratification and genetic counseling. [1]

First RNA interference therapy for acute hepatic porphyria

The U.S. Food and Drug Administration approves givosiran, an RNA interference drug that targets hepatic ALAS1, providing a novel treatment option that reduces the frequency of attacks in adults with acute hepatic porphyria.


FAQ
What is porphyria, in simple terms?
Porphyria is a group of rare genetic disorders in which the body has trouble making heme, a component of hemoglobin that carries oxygen in the blood. This problem causes certain chemicals called porphyrins and their precursors to build up, which can damage the nervous system, skin, liver, or other organs and lead to attacks of severe pain, skin blistering, or other symptoms. [1]
What are the main types of porphyria, and how do they differ?
Porphyrias are usually divided into “acute” and “cutaneous” types. Acute hepatic porphyrias mainly affect the nervous system and liver, often causing sudden attacks of severe abdominal pain, weakness, and neurological or psychiatric symptoms. Cutaneous porphyrias primarily affect the skin, especially on sun‑exposed areas, and can cause blistering, fragility, and scarring. Some forms, such as variegate porphyria and hereditary coproporphyria, can produce both acute and skin symptoms.
Why can porphyria be so hard to diagnose?
Porphyria is difficult to diagnose because its symptoms often mimic more common conditions, such as irritable bowel syndrome, gallbladder disease, anxiety, or other skin disorders. Attacks can be intermittent, so test results may appear normal between episodes, and not all laboratories are equipped to perform specialized porphyrin testing. As a result, people may see many providers over the years before the correct diagnosis is made, unless clinicians specifically consider porphyria and order targeted tests during or soon after an attack.
What usually triggers a porphyria attack?
In acute hepatic porphyrias, attacks are often triggered when something increases the body’s demand for heme. Common triggers include certain medications, alcohol, smoking, hormonal changes (such as progesterone surges in the menstrual cycle), fasting or crash diets, infections, and stress. Identifying and avoiding individual triggers is a key part of long‑term management, along with working closely with clinicians to review drugs for safety in porphyria.
How does sunlight affect people with cutaneous porphyria?
In cutaneous porphyrias, excess porphyrins accumulate in the skin and react to ultraviolet and visible light, causing tissue damage. Even relatively short sun exposure can lead to pain, redness, swelling, or fragile, blistering skin, particularly on the hands and face. People often need strict sun protection strategies, such as protective clothing, wide‑brimmed hats, careful timing of outdoor activities, and sometimes the use of physical (mineral) sunscreens that block both UVA and visible light.
Is porphyria always inherited, and can family members be tested?
Most porphyrias are inherited, typically in an autosomal dominant or autosomal recessive pattern, although not everyone who carries a gene change will develop symptoms. Because of this genetic basis, first‑degree relatives of an affected person are often advised to consider genetic counseling and, when appropriate, biochemical or DNA testing. Early identification of at‑risk family members can help them avoid known triggers and monitor for complications before serious problems occur.
How is porphyria managed over the long term?
Long‑term management focuses on preventing attacks, treating complications, and addressing quality of life. This can include avoiding specific drugs and triggers, maintaining regular meals and adequate carbohydrate intake, using specialized treatments such as hemin or newer RNA‑targeted therapies for some acute hepatic porphyrias, and managing pain and mental health needs. People often work with a multidisciplinary team that may include specialists in hematology, hepatology, dermatology, genetics, and pain management, as well as patient advocacy organizations that offer education and support.